Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer
NCT: NCT07645118 · NOT_YET_RECRUITING
Brief Summary
This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.
Frequently Asked Questions
What is Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer?
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer is a clinical trial registered under NCT07645118. Current status: NOT_YET_RECRUITING.
What is the status of NCT07645118?
The current status of NCT07645118 (Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer) is: NOT_YET_RECRUITING.
When did Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer start?
Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer started on 2026-07.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.